Dr. Anthony Sedgwick has held executive positions in a large number of life science companies in the UK and continental Europe. Most recently he served as the Chief Business Officer of Silence Therapeutics plc. Previously, Dr. Sedgwick was Chief Executive Officer of Daniolabs Ltd. and Cambridge Biotechnology Ltd. He successfully developed both companies and created valuable exits by trade sale.
Prior to his move into biotechnology, Dr. Sedgwick had a long and successful clinical development career at Roche, where he was the Global Head of Clinical Operations and U.K. Development Director. During his long research career, he gained valuable experience in infectious disease and had also extensively studied Propionibacterium acnes.
Dr. Werner Wolf has been the science and technology advisor to TVM Capital since 1994. He also became acquainted with EU policy on various levels: IP, regulatory and research policy, as well as regional development aspects. He was on the supervisory board of several companies. Since 2008 Dr. Wolf started his consulting company Bio Innovations in Switzerland focusing on translation of science towards commercialization on various levels. He serves as a biotechnology business advisor at the INITS start-up advisory center in Vienna.
Dr. Gottfried Himmler has been actively involved in the set-up of several biotech companies including f-star and Igeneon where he served as Chief Scientific Officer and Managing Director. He is a Member of the Supervisory Board at Heliovis AG. Prior to his entrepreneurial activities, Mr. Himmler was Assistant Professor at the Institute of Applied Microbiology in Vienna, Austria. He is lecturing Management and Entrepreneurship at the University of Applied Sciences in Vienna and is named inventor on more than 240 patents and patent applications (resulting from more than 37 patent families). He received his Doctorate from the University of Applied Life Sciences in Vienna, Austria.